Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 6 chart positions in 6 markets.
By chart position
- 🇬🇧GB · Science#1925K to 30K
- 🇰🇷KR · Science#1351K to 10K
- 🇮🇹IT · Science#1361K to 10K
- 🇭🇰HK · Science#4110K to 30K
- 🇵🇱PL · Science#953K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
12K to 50K🎙 ~2x weekly·196 episodes·Last published 1w ago - Monthly Reach
Unique listeners across all episodes (30 days)
23K to 100K🇬🇧30%🇭🇰30%🇰🇷10%+3 more - Active Followers
Loyal subscribers who consistently listen
9.2K to 40K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 12 epsHost
Recent guests
Recent episodes
Ep203: Sri Kosuri on Small Molecule Correctors of Disease
Jun 16, 2026
Unknown duration
Ep202: Becky Pferdehirt on Reimagining Science for the AI Era
Jun 2, 2026
1h 08m 12s
Ep201: Jeremy Levin on Biotech in the Balance
May 19, 2026
1h 08m 40s
Ep200: Richard Pops Reflects on a 35-Year Career in Biotech
May 5, 2026
1h 13m 31s
Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era
Apr 21, 2026
1h 10m 08s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/16/26 | Ep203: Sri Kosuri on Small Molecule Correctors of Disease | Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to correct protein misfolding and mistrafficking at the root of many diseases. | — | ||||||
| 6/2/26 | Ep202: Becky Pferdehirt on Reimagining Science for the AI Era✨ | AI in biologylife sciences+3 | Becky Pferdehirt | RadialAstera Institute | Emeryville, CA | AIbiology+3 | — | 1h 08m 12s | |
| 5/19/26 | Ep201: Jeremy Levin on Biotech in the Balance✨ | biotechindustry trust+3 | Jeremy Levin | Ovid TherapeuticsBiotech in the Balance | — | biotechOvid Therapeutics+5 | — | 1h 08m 40s | |
| 5/5/26 | Ep200: Richard Pops Reflects on a 35-Year Career in Biotech✨ | sleep disordersorexin drugs+3 | Richard Pops | AlkermesThe Long Run with Luke Timmerman | — | Orexinsleep disorders+5 | — | 1h 13m 31s | |
| 4/21/26 | Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era✨ | small molecule medicinesAI in chemistry+3 | Marty Burke | University of IllinoisExcelsior Sciences | — | small moleculesAI+3 | — | 1h 10m 08s | |
| 4/7/26 | Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery✨ | drug discoverycomputation+3 | Abbas Kazimi | Nimbus Therapeutics | Boston | drug discoverycomputation+3 | — | 1h 16m 43s | |
| 3/31/26 | Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature✨ | drug discoverynatural products+3 | Viswa Colluru | Enveda | Boulder, Colo. | drug discoverynatural products+3 | — | 1h 16m 57s | |
| 3/17/26 | Ep196: Otello Stampacchia on Europe's Biotech Crisis✨ | biotech investmentEurope+3 | Otello Stampacchia | Omega Funds | Europebiotech | biotechinvestment+5 | — | 1h 03m 17s | |
| 3/3/26 | Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases✨ | T-cell engagersautoimmune diseases+3 | Ken Song | Candid Therapeutics | San Diego | T-cell engagersautoimmune diseases+3 | — | 1h 05m 45s | |
| 2/17/26 | Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery✨ | CancerAutoimmune Drug Discovery+3 | Ansu Satpathy | Timmerman Report | — | cancerautoimmune+3 | — | 1h 08m 54s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 1/22/26 | Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines✨ | GLP-1 medicinesweight loss+3 | Ron Renaud | Kailera Therapeutics | Waltham, Mass. | GLP-1weight loss+3 | — | 1h 05m 10s | |
| 1/8/26 | Ep192: Kate Haviland on Following the Science to Precision Immunology✨ | precision immunologybiotechnology+3 | Kate Haviland | Blueprint MedicinesSanofi | — | Kate HavilandBlueprint Medicines+5 | — | 1h 26m 06s | |
| 12/15/25 | Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease✨ | kidney diseasebiotechnology+3 | Emily Conley | Renasant Bioautosomal dominant polycystic kidney disease (ADPKD) | Berkeley, CA | ADPKDsmall molecule correctors+3 | — | 1h 07m 34s | |
| 11/20/25 | Ep190: Neil Kumar on Building a Rare Disease Drug Company | Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer. | — | ||||||
| 11/12/25 | Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI | Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI. | — | ||||||
| 10/28/25 | Ep188: Art Krieg on Innate Immune System Activators for Cancer | Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer. | — | ||||||
| 10/14/25 | Ep187: Eric Fischer on Creating a New Class of Medicines | Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders. | — | ||||||
| 9/29/25 | Ep186: Bruce Levine & Mags McCarthy on a Song About Science and Hope | Bruce Levine, a CAR-T cell therapy researcher at the University of Pennsylvania, and Mags McCarthy, a country music star, discuss their new song about science and hope for cancer patients. | — | ||||||
| 9/17/25 | Ep185: Dr. Lachelle Weeks on Predicting Leukemia Risk At Scale | Dr. Lachelle Weeks is a physician-scientist at Dana-Farber Cancer Institute working on a project to predict leukemia risk based on widely available blood samples. | — | ||||||
| 8/28/25 | Ep184: Jen Adair on Affordable, Accessible Gene & Cell Therapies | Jen Adair, professor and associate director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School, on creating more affordable and accessible cell and gene therapies. | — | ||||||
| 8/6/25 | Ep183: Sabah Oney on CAR-T Cells Against Solid Tumors | Sabah Oney, CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics, on engineering CAR-T cells that can kill solid tumors. | — | ||||||
| 7/23/25 | Ep182: Andy Rachleff & Yung Lie on Creative Ways to Back Science | Andy Rachleff and Yung Lie, board chair and CEO of Damon Runyon Cancer Research Foundation, on creative ways to support science amid budget cuts. | — | ||||||
| 7/1/25 | Ep181: Claire Mazumdar on a Two-Pronged Attack Against Cancer | Claire Mazumdar, CEO of Boston-based Bicara Therapeutics, on developing a bifunctional antibody for head and neck cancer. | — | ||||||
| 6/11/25 | Ep180: John Rinn on Discovering Drugs Based on Long Non-Coding RNA | John Rinn, professor at the University of Colorado and co-founder of Lincswitch Therapeutics, on exploring long non-coding RNA. | — | ||||||
| 5/28/25 | Ep179: Ethan Weiss & Josh Lehrer on a New Idea for Cardiovascular Disease & Diabetes | Marea Therapeutics CEO Josh Lehrer and CSO Ethan Weiss on a new angle of attack against cardiovascular disease and diabetes. | — | ||||||
Showing 25 of 201
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
6 placements across 6 markets.
Chart Positions
6 placements across 6 markets.